ImmuneBridge
Private Company
Funding information not available
Overview
ImmuneBridge is a Boston-based biotech founded in 2019, focused on revolutionizing cell therapy development through an integrated platform of ML-driven screening and scalable manufacturing. The company utilizes young, healthy umbilical cord blood units from public banks as a diverse and high-quality starting material to produce various immune cell types, including HSCs, NK cells, and T cells. By addressing universal pain points like high cost and poor manufacturability, ImmuneBridge is positioning itself as an enabling platform for partners in academia and industry. The company is currently in a pre-clinical, platform-validation stage, building partnerships to advance novel therapies toward the clinic.
Technology Platform
Integrated platform combining ML-powered screening of umbilical cord blood donors/constructs with proprietary stem cell expansion technology to design and manufacture scalable cell therapies (HSCs, NK cells, T cells, etc.).
Opportunities
Risk Factors
Competitive Landscape
ImmuneBridge competes with other cell therapy platform and manufacturing technology companies (e.g., Century Therapeutics, Shoreline Biosciences, Cellares) and large biopharma with internal capabilities. Its differentiation lies in the specific use of curated umbilical cord blood and its integrated ML screening and expansion system.